Gossamer Bio, Inc (NASDAQ:GOSS) is one of the 10 Best High-Risk Penny Stocks to Buy Right Now. Gossamer Bio, Inc (NASDAQ:GOSS ...

Gossamer Bio, Inc. (NASDAQ:GOSS) is included in our list of the 10 most active penny stocks to buy. As of March 16, 2026, ...

Fintel reports that on March 23, 2026, Cantor Fitzgerald downgraded their outlook for Gossamer Bio (NasdaqGS:GOSS) from ...

Gossamer Bio reported last month that its only late-stage candidate failed a Phase 3 study in pulmonary arterial hypertension ...

A California-based biotech company announced it will be cutting roughly half of its workforce after a disappointing study ...

The company's stock value has tanked before - it was once worth $1 billion.

The average fair value estimate on Gossamer Bio has reset from about US$9.50 to roughly US$3.69, signaling a steep reassessment of what analysts think the shares may be worth. That shift lines up with ...

Gossamer Bio Inc. (GOSS) on Tuesday reported a loss of $47.2 million in its fourth quarter. On a per-share basis, the San ...

View source version on businesswire.com: https://www.businesswire.com/news/home/20250313732742/en/ For Investors and Media: Bryan Giraudo, Chief Financial Officer ...

- Gossamer to Present Preclinical Evidence of Synergistic Treatment Effect from Combination Seralutinib & Sotatercept in Models of PAH - “Gossamer is committed to generating and presenting data that ...

Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension ...

When Gossamer Bio announced poor results from its flagship blood pressure study in February, the San Diego company’s stock ...